Biomarkers in Samples From Young Patients With Neuroblastoma
|ClinicalTrials.gov Identifier: NCT01358604|
Recruitment Status : Completed
First Posted : May 23, 2011
Last Update Posted : April 15, 2016
RATIONALE: Studying samples of tissue and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study studies biomarkers in samples from young patients with neuroblastoma.
|Condition or disease||Intervention/treatment|
|Neuroblastoma||Genetic: polymerase chain reaction Genetic: protein expression analysis Genetic: western blotting Other: flow cytometry Other: immunohistochemistry staining method Other: laboratory biomarker analysis|
- To analyze the expression of ROR1 on the surface of primary neuroblastoma cells.
- To investigate the therapeutic potential of anti-ROR1 monoclonal antibodies (mAbs), bispecific antibodies, and immunotoxins in in vitro and in vivo models of neuroblastoma.
OUTLINE: Archived bone marrow and tumor tissue samples are analyzed for ROR1 expression by flow cytometry, western blotting, qPCR, and IHC.
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||ROR1 as a Novel Target for Neuroblastoma|
|Study Start Date :||May 2011|
|Actual Primary Completion Date :||April 2016|
|Actual Study Completion Date :||April 2016|
- ROR1 is expressed on the surface of neuroblastoma cells and constitutes a suitable target for mAb therapy
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01358604
|Principal Investigator:||David Hema, MD, MPH||NCI - Experimental Transplantation and Immunology Branch|